Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model

International Journal of Antimicrobial Agents

Volumn 48, Issue 5, 2016, Pages 559-563

  Liu, Xiaofen ^a,b,c   Zhao, Miao ^a,b   Chen, Yuancheng ^a,b   Bian, Xingchen ^d   Li, Yunfei ^c   Shi, Jun ^c   Zhang, Jing ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Municipal Commission of Population and Family Planning   (China)

^c Roche Innovation Center Shanghai   (China)

^d SHANGHAI NORMAL UNIVERSITY   (China)

Author keywords

Carbapenem resistant Acinetobacter baumannii; Colistin; Combination therapy; In vitro; Meropenem; PK PD model

Indexed keywords

CARBAPENEM; COLISTIN; MEROPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BIOASSAY; CHEQUERBOARD ASSAY; CHINESE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTION; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BETA-LACTAM RESISTANCE; CARBAPENEMS; COLISTIN; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, BIOLOGICAL; THIENAMYCINS;

EID: 84994017945     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.07.018     Document Type: Article

References (20)

1. [1] Kim, U.J., Kim, H.K., An, J.H., Cho, S.K., Park, K.-H., Jang, H.-C., Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J 50 (2014), 37–44.
2. [2] Farrell, D.J., Sader, H.S., Flamm, R.K., Jones, R.N., Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 43 (2014), 533–539.
3. [3] Hu, F., Zhu, D., Wang, F., Jiang, X., Xu, Y., Zhang, X., et al. CHINET 2014 surveillance of bacterial resistance in China. Chin J Infect Chemother 15 (2015), 401–410.
4. [4] Linden, P., Safety profile of meropenem. Drug Saf 30 (2007), 657–668.
5. [5] Frei, C.R., Wiederhold, N.P., Burgess, D.S., Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61 (2008), 621–628.
6. [6] Cooper, T.W., Pass, S.E., Brouse, S.D., Hall, R.G.I.I., Can pharmacokinetic and pharmacodynamic principles be applied to the treatment of multidrug-resistant Acinetobacter?. Ann Pharmacother 45 (2011), 229–240.
7. [7] Cai, Y., Chai, D., Wang, R., Liang, B., Bai, N., Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67 (2012), 1607–1615.
8. [8] Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii. A multicentre, randomised, clinical trial. Clin Infect Dis 57 (2013), 349–358.
9. [9] van Belkum, A., Halimi, D., Bonetti, E.-J., Renzi, G., Cherkaoui, A., Sauvonnet, V., et al. Meropenem/colistin synergy testing for multidrug-resistant Acinetobacter baumannii strains by a two-dimensional gradient technique applicable in routine microbiology. J Antimicrob Chemother 70 (2015), 167–172.
10. [10] Bartual, S.G., Seifert, H., Hippler, C., Luzon, M.A., Wisplinghoff, H., Rodriguez-Valera, F., Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 43 (2005), 4382–4390.
11. [11] Tan, T.Y., Lim, T.P., Lee, W.H.L., Sasikala, S., Hsu, L.Y., Kwa, A.L.-H., In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time–kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 55 (2011), 436–438.
12. [12] Liang, W., Chen, Y., Cao, Y., Liu, X., Huang, J., Hu, J., et al. Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 57 (2013), 2942–2947.
13. [13] Zhao, C., Li, J., Zhang, L., Zhang, P., Liu, Y., Pharmacokinetics of meropenem single dose intravenous in healthy volunteers. Chin J Clin Pharmacol 20 (2004), 189–192.
14. [14] Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
15. [15] Vourli, S., Frantzeskaki, F., Meletiadis, J., Stournara, L., Armaganidis, A., Zerva, L., et al. Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. Int J Antimicrob Agents 45 (2015), 670–671.
16. [16] Zhao, M., Wu, X., Fan, Y., Zhang, J., Zhang, Y., Yu, J., et al. Population pharmacokinetics (PPK) of colistimethate sodium (CMS) and formed colistin (COL) in patients with hospital-acquired pneumonia. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/28th International Congress of Chemotherapy (ICC), 2015, ASM Press, Washington, DC 17–21 September 2015; San Diego, CA; [poster].
17. [17] Mohamed, A.F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56 (2012), 4241–4249.
18. [18] Dudhani, R.V., Turnidge, J.D., Nation, R.L., Li, J., fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65 (2010), 1984–1990.
19. [19] Cheah, S.E., Wang, J., Nguyen, V.T., Turnidge, J.D., Li, J., Nation, R.L., New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70 (2015), 3291–3297.
20. [20] Hagihara, M., Housman, S.T., Nicolau, D.P., Kuti, J.L., In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 58 (2014), 874–879.